Press Release —
The multinational
Hikma Pharmaceuticals PLC (Hikma) announced a new exclusive
licensing agreements with Celltrion Healthcare Co., Ltd. for CT-P43, or
ustekinumab, a monoclonal antibody that is a proposed biosimilar to Janssen’s
Stelara, according to a press statement.
اضافة اعلان
Under the terms of
the agreement, Hikma will have exclusive rights to commercialize CT-P43 in its
Middle East and North Africa (MENA) markets, and that Celltrion Healthcare will
develop, manufacture and supply CT-P43 to Hikma.
The deal will help
equip doctors and patients with more treatment options across the region. This
agreement also builds on Celltrion Healthcare and Hikma’s existing partnership
in MENA, adding another immunology biosimilar to Hikma’s portfolio, a key focus
of its strategy.
CT-P43 is an
important drug used in the treatment of autoimmune diseases, such as Crohn’s
disease and ulcerative colitis.
“We are excited to
add CT-P43 to our portfolio, strengthening our offering of biosimilar and
innovative biologic products.” said Mazen Darwazah, Hikma’s executive vice
chairman and
MENA president.
“CT-P43 is the
sixth immunology biologic we add to our portfolio in MENA,” he said. “This new
addition enables us to increase patients’ access to important specialty
products, helping them in their treatment journey for these difficult
diseases.”
The press statement
said CT-P43 is a biosimilar to Janssen’s Stelara, which is a human monoclonal
antibody that inhibits the bioactivity of human IL-12 and IL-23 by preventing
shared p40 from binding to the IL-12R 1 receptor protein expressed on the
surface of immune cells. IL-12 and IL-23 are involved in inflammatory and
immune responses, such as natural killer cell activation, and CD4+ T-cell
differentiation and activation.
IL-12 and IL-23
have been implicated as important contributors to the chronic inflammation that
is a hallmark of Crohn’s disease and ulcerative colitis, among many other
autoimmune diseases.
Read more Business
Jordan News
.jpg)
.jpg)
